Horizon Therapeutics plc (HZNP) announced the FDA has approved the supplemental Biologics License Application expanding the labeling to include KRYSTEXXA injection co-administered with methotrexate, for adults living with uncontrolled gout. The expanded labeling for KRYSTEXXA with methotrexate is based on the results from the MIRROR randomized controlled trial.
"We anticipate this approval will encourage more physicians to recommend KRYSTEXXA with methotrexate to help their patients with uncontrolled gout receive the full benefits of KRYSTEXXA," said Elizabeth Thompson, executive vice president, research and development, Horizon.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.